Nanobiotix (NBTX) Competitors

Nanobiotix (NASDAQ:NBTX) and CureVac (NASDAQ:CVAC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, community ranking, valuation, analyst recommendations, media sentiment, profitability and earnings.

Does the media refer more to NBTX or CVAC?

In the previous week, Nanobiotix had 1 more articles in the media than CureVac. MarketBeat recorded 9 mentions for Nanobiotix and 8 mentions for CureVac. CureVac's average media sentiment score of 0.99 beat Nanobiotix's score of 0.83 indicating that CureVac is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nanobiotix	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CureVac	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate NBTX or CVAC?

Nanobiotix presently has a consensus price target of $12.00, indicating a potential upside of 230.67%. CureVac has a consensus price target of $10.00, indicating a potential upside of 235.57%. Given CureVac's higher possible upside, analysts clearly believe CureVac is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanobiotix	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
CureVac	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25

Which has stronger earnings & valuation, NBTX or CVAC?

Nanobiotix has higher earnings, but lower revenue than CureVac.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanobiotix	$36.22M	4.72	-$42.97M	N/A	N/A
CureVac	$543.28M	1.23	-$281.58M	$0.55	5.42

Do institutionals and insiders believe in NBTX or CVAC?

38.8% of Nanobiotix shares are held by institutional investors. Comparatively, 17.3% of CureVac shares are held by institutional investors. 3.5% of Nanobiotix shares are held by insiders. Comparatively, 2.2% of CureVac shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Is NBTX or CVAC more profitable?

CureVac has a net margin of 20.72% compared to Nanobiotix's net margin of 0.00%. CureVac's return on equity of 21.98% beat Nanobiotix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanobiotix	N/A	N/A	N/A
CureVac	20.72%	21.98%	15.72%

Which has more risk & volatility, NBTX or CVAC?

Nanobiotix has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500. Comparatively, CureVac has a beta of 2.53, meaning that its stock price is 153% more volatile than the S&P 500.

Does the MarketBeat Community believe in NBTX or CVAC?

CureVac received 15 more outperform votes than Nanobiotix when rated by MarketBeat users. However, 61.11% of users gave Nanobiotix an outperform vote while only 55.32% of users gave CureVac an outperform vote.

Company	Underperform	Outperform
Nanobiotix	Outperform Votes 11 61.11%	Underperform Votes 7 38.89%
CureVac	Outperform Votes 26 55.32%	Underperform Votes 21 44.68%

Summary

Nanobiotix and CureVac tied by winning 8 of the 16 factors compared between the two stocks.